Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
Condition: B-Precursor ALL · Sponsor: Goethe University
About this study
The trial proposed here attempts to reduce induction chemotherapy to phase I of standard induction in patients with B-precursor ALL. Induction phase II will be replaced by blinatumomab. The initial treatment phase is followed by sequential chemotherapy and further blinatumomab cycles.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (21)
| University Hospital of Frankfurt (Main) | Frankfurt am Main, Hesse, Germany | — |
| Uniklinik RWTH Aachen | Aachen, Germany | — |
| Charité - Campus Benjamin Franklin | Berlin, Germany | — |
| Vivantes Klinikum Neukölln | Berlin, Germany | — |
| Städtisches Klinikum Braunschweig | Braunschweig, Germany | — |
| Klinikum Bremen Mitte | Bremen, Germany | — |
| Evangelisches Krankenhaus Essen-Werden | Essen, Germany | — |
| Universitätsklinikum Halle | Halle, Germany | — |
| Uniklinik Hamburg Eppendorf | Hamburg, Germany | — |
| Evangelisches Krankenhaus Hamm | Hamm, Germany | — |
| Städtisches Klinikum Karlsruhe | Karlsruhe, Germany | — |
| Universitätsklinikum Schleswig-Holstein | Kiel, Germany | — |
+ 9 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03480438